Botanix Pharmaceuticals (BOT) Stock Overview
A pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BOT Community Fair Values
Create NarrativeSee what 77 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Botanix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.018 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.018 |
| Beta | 0.86 |
| 1 Month Change | -10.00% |
| 3 Month Change | -18.18% |
| 1 Year Change | -85.60% |
| 3 Year Change | -90.27% |
| 5 Year Change | -74.29% |
| Change since IPO | -40.00% |
Recent News & Updates
Analysts Have Made A Financial Statement On Botanix Pharmaceuticals Limited's (ASX:BOT) Yearly Report
Botanix Pharmaceuticals Limited ( ASX:BOT ) just released its latest yearly report and things are not looking great. It...
BOT: Commercial Launch Execution Will Drive Future Upside Potential
Analysts have reset their price expectations for Botanix Pharmaceuticals, cutting the fair value estimate from A$0.21 to A$0.14. They cite updated assumptions for discount rate, revenue growth, profit margins, and a lower future P/E multiple.
BOT: Future Share Dilution From Large Capital Raising Will Drive Upside Potential
Analysts have reset their fair value estimate for Botanix Pharmaceuticals from A$0.83 to A$0.49, reflecting updated assumptions for the discount rate, revenue growth, profit margins, and a much lower future P/E multiple. What's in the News Botanix Pharmaceuticals completed a follow on equity offering of A$4.999999 million in ordinary shares, comprising 14,341,646 securities at A$0.06 each with attached options, plus an additional 68,991,667 ordinary shares at A$0.06 each with attached options.Recent updates
Analysts Have Made A Financial Statement On Botanix Pharmaceuticals Limited's (ASX:BOT) Yearly Report
Botanix Pharmaceuticals Limited ( ASX:BOT ) just released its latest yearly report and things are not looking great. It...BOT: Commercial Launch Execution Will Drive Future Upside Potential
Analysts have reset their price expectations for Botanix Pharmaceuticals, cutting the fair value estimate from A$0.21 to A$0.14. They cite updated assumptions for discount rate, revenue growth, profit margins, and a lower future P/E multiple.BOT: Future Share Dilution From Large Capital Raising Will Drive Upside Potential
Analysts have reset their fair value estimate for Botanix Pharmaceuticals from A$0.83 to A$0.49, reflecting updated assumptions for the discount rate, revenue growth, profit margins, and a much lower future P/E multiple. What's in the News Botanix Pharmaceuticals completed a follow on equity offering of A$4.999999 million in ordinary shares, comprising 14,341,646 securities at A$0.06 each with attached options, plus an additional 68,991,667 ordinary shares at A$0.06 each with attached options.
Bullish View That A Scalable Dermatology Platform Will Transform An Underserved Hyperhidrosis Market
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on commercialising Sofdra for primary axillary hyperhidrosis and leveraging its U.S. commercial platform. What are the underlying business or industry changes driving this perspective?Single Product And API Constraints Will Shape Dermatology Platform Potential Over The Long Term
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis supported by its own fulfillment platform. What are the underlying business or industry changes driving this perspective?Long-Term Hyperhidrosis Demand And Fulfillment Platform Will Support This Bullish Thesis
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis. What are the underlying business or industry changes driving this perspective?Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Botanix...Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Botanix Pharmaceuticals...We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Shareholder Returns
| BOT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -5.3% | -3.6% | -2.5% |
| 1Y | -85.6% | -11.2% | -2.9% |
Return vs Industry: BOT underperformed the Australian Pharmaceuticals industry which returned -11.2% over the past year.
Return vs Market: BOT underperformed the Australian Market which returned -2.9% over the past year.
Price Volatility
| BOT volatility | |
|---|---|
| BOT Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 16.6% |
| 10% least volatile stocks in AU Market | 3.8% |
Stable Share Price: BOT has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: BOT's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Howie McKibbon | www.botanixpharma.com |
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus.
Botanix Pharmaceuticals Limited Fundamentals Summary
| BOT fundamental statistics | |
|---|---|
| Market cap | AU$49.26m |
| Earnings (TTM) | -AU$69.77m |
| Revenue (TTM) | AU$33.80m |
Is BOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOT income statement (TTM) | |
|---|---|
| Revenue | AU$33.80m |
| Cost of Revenue | AU$14.35m |
| Gross Profit | AU$19.45m |
| Other Expenses | AU$89.22m |
| Earnings | -AU$69.77m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 57.55% |
| Net Profit Margin | -206.41% |
| Debt/Equity Ratio | 0% |
How did BOT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/17 08:53 |
| End of Day Share Price | 2026/09/17 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Botanix Pharmaceuticals Limited is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madeleine Williams | Canaccord Genuity |
| Joseph Pantginis | H.C. Wainwright & Co. |